First Study of Oral Artenimol-R in Advanced Cervical Cancer: Clinical Benefit, Tolerability and Tumor Markers

Publication type:
Journal article
Metadata:
Autoren
  • Frans Herwig Jansen
  • Innocent Adoubi
  • Kouassi JC Comoe
  • Tinne De Cnodder
  • Nicolas Jansen
  • Alexander Tschulakow
  • Thomas Efferth
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000298514300049&DestLinkType=FullRecord&DestApp=WOS_CPL
eISSN
1791-7530
Externe Identifier
  • Clarivate Analytics Document Solution ID: 868HM
  • PubMed Identifier: 22199309
ISSN
0250-7005
Ausgabe der Veröffentlichung
12
Zeitschrift
ANTICANCER RESEARCH
Schlüsselwörter
  • Cervical cancer
  • artesunate
  • artenimol
  • clinical symptoms
  • tumour markers
Paginierung
4417 - 4422
Datum der Veröffentlichung
2011
Status
Published
Titel
First Study of Oral Artenimol-R in Advanced Cervical Cancer: Clinical Benefit, Tolerability and Tumor Markers
Sub types
  • Article
Ausgabe der Zeitschrift
31

Data source: Web of Science (Lite)

Other metadata sources:
Abstract
<h4>Background/aim</h4>Artenimol-R is cytotoxic in transformed cervical cells and safety in humans is yet to be established. The present study investigates the clinical benefits, safety and the tumor marker effect of orally administered Artenimol-R in patients with advanced cervix carcinoma.<h4>Patients and methods</h4>Ten patients were treated with Artenimol-R for 28 days. Clinical symptoms, vaginal discharge and pain were followed-up. Adverse events were recorded. Biopsy samples were analyzed by immunohistochemistry for the expression of relevant tumor markers.<h4>Results</h4>Artenimol-R treatment induced clinical remission with a median time for the disappearance of the symptoms being 7 days. No adverse events of grade 3 or 4 occurred. The expression of p53, Epidermal growth factor receptor (EGFR), and antigen Ki-67 as a cellular marker of proliferation, as well as the number of blood vessels stained by the CD31 antibody decreased, whereas the expression of transferrin receptor protein 1 (CD71) increased.<h4>Conclusion</h4>The current pilot study provides evidence on the improvement of the clinical symptoms and the good tolerability of Artenimol-R in patients with advanced carcinoma of the cervix uteri. A survival trial with Artenimol-R in advanced patients is warranted.
Addresses
  • Dafra Pharma Ltd, Slachthuisstraat 30 b7, 2300 Turnhout, Belgium. fhj@dafra.be
Autoren
  • Frans Herwig Jansen
  • Innocent Adoubi
  • Kouassi Comoe J C
  • Tinne DE Cnodder
  • Nicolas Jansen
  • Alexander Tschulakow
  • Thomas Efferth
eISSN
1791-7530
Externe Identifier
  • PubMed Identifier: 22199309
Open access
false
ISSN
0250-7005
Ausgabe der Veröffentlichung
12
Zeitschrift
Anticancer research
Schlüsselwörter
  • Humans
  • Carcinoma
  • Artemisinins
  • Receptors, Transferrin
  • Ki-67 Antigen
  • Antineoplastic Agents
  • Antigens, CD
  • Treatment Outcome
  • Remission Induction
  • Immunohistochemistry
  • Administration, Oral
  • Follow-Up Studies
  • Adult
  • Aged
  • Middle Aged
  • Uterine Cervical Neoplasms
  • Female
  • ErbB Receptors
  • Biomarkers, Tumor
  • Platelet Endothelial Cell Adhesion Molecule-1
Sprache
eng
Medium
Print
Paginierung
4417 - 4422
Datum der Veröffentlichung
2011
Status
Published
Datum der Datenerfassung
2011
Titel
First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers.
Sub types
  • Clinical Trial
  • Journal Article
Ausgabe der Zeitschrift
31

Data source: Europe PubMed Central

Abstract
BACKGROUND/AIM: Artenimol-R is cytotoxic in transformed cervical cells and safety in humans is yet to be established. The present study investigates the clinical benefits, safety and the tumor marker effect of orally administered Artenimol-R in patients with advanced cervix carcinoma. PATIENTS AND METHODS: Ten patients were treated with Artenimol-R for 28 days. Clinical symptoms, vaginal discharge and pain were followed-up. Adverse events were recorded. Biopsy samples were analyzed by immunohistochemistry for the expression of relevant tumor markers. RESULTS: Artenimol-R treatment induced clinical remission with a median time for the disappearance of the symptoms being 7 days. No adverse events of grade 3 or 4 occurred. The expression of p53, Epidermal growth factor receptor (EGFR), and antigen Ki-67 as a cellular marker of proliferation, as well as the number of blood vessels stained by the CD31 antibody decreased, whereas the expression of transferrin receptor protein 1 (CD71) increased. CONCLUSION: The current pilot study provides evidence on the improvement of the clinical symptoms and the good tolerability of Artenimol-R in patients with advanced carcinoma of the cervix uteri. A survival trial with Artenimol-R in advanced patients is warranted.
Autoren
  • Frans Herwig Jansen
  • Innocent Adoubi
  • Kouassi Comoe J C
  • Tinne DE Cnodder
  • Nicolas Jansen
  • Alexander Tschulakow
  • Thomas Efferth
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/22199309
eISSN
1791-7530
Ausgabe der Veröffentlichung
12
Zeitschrift
Anticancer Res
Schlüsselwörter
  • Administration, Oral
  • Adult
  • Aged
  • Antigens, CD
  • Antineoplastic Agents
  • Artemisinins
  • Biomarkers, Tumor
  • Carcinoma
  • ErbB Receptors
  • Female
  • Follow-Up Studies
  • Humans
  • Immunohistochemistry
  • Ki-67 Antigen
  • Middle Aged
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Receptors, Transferrin
  • Remission Induction
  • Treatment Outcome
  • Uterine Cervical Neoplasms
Sprache
eng
Country
Greece
Paginierung
4417 - 4422
PII
31/12/4417
Datum der Veröffentlichung
2011
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2012
Titel
First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers.
Sub types
  • Clinical Trial
  • Journal Article
Ausgabe der Zeitschrift
31

Data source: PubMed

Beziehungen:
Property of

Tools